Malignant hyperthermia and ECT
- 1 August 1986
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 143 (8) , 1027-1029
- https://doi.org/10.1176/ajp.143.8.1027
Abstract
The malignant hyperthermia syndrome is a rare hypermetabolic state that occurs in patients after the administration of certain drugs, most frequently anesthetics and/or succinylcholine. In view of the widespread use of succinylcholine to induce muscle relaxation prior to ECT, It is important that the individual who administers succinylcholine in this setting be familiar with the syndrome and its treatment. This report reviews what is known about malignant hyperthermia and proposes a course of action when the syndrome occurs in a patient undergoing ECT or a patient with known susceptibility to malignant hyperthermia needs ECT.This publication has 8 references indexed in Scilit:
- Dantrolene Dose Response in Awake ManAnesthesiology, 1983
- Halothane-induced ATP Depletion in Platelets from Patients Susceptible to Malignant Hyperthermia and from ControlsAnesthesiology, 1983
- ECT use for a patient with malignant hyperthermiaAmerican Journal of Psychiatry, 1982
- Dantrolene in Human Malignant Hyperthermia A Multicenter StudyAnesthesiology, 1982
- Malignant Hyperthermia Following Preoperative Oral Administration of DantroleneAnesthesiology, 1981
- HALOPERIDOL-INDUCED COMATOSE STATE WITH HYPERTHERMIA AND RIGIDITY IN ADOLESCENCE - 2 CASE-REPORTS WITH A LITERATURE-REVIEW1979
- Use of cryostat sections for measurement of Ca2+ uptake by sarcoplasmic reticulumAnalytical Biochemistry, 1978
- Muscle Rigidity Following Administration of SuccinylcholineAnesthesiology, 1968